報價延遲最少15分鐘:2026/10/01 18:23 EDT
盤後時段
|
||||
|
80.83 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
78.64
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.86/2.34
|
|
企業價值
3.40B
|
| 資產負債 |
|
每股賬面淨值
14.94
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
605.49M
|
|
每股收益
5.53
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The companyhas developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
